What can we expect in PCI in patients with chronic coronary artery disease-indication of PCI for angiographically significant coronary artery stenosis without objective evidence of myocardial ischemia (con) -

Circulation Journal

Volumn 75, Issue 1, 2011, Pages 211-217

  Akasaka, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Coronary artery bypass grafting; Coronary artery disease; Ischemia; Percutaneous coronary intervention (PCI); Stents

Indexed keywords

ANGIOCARDIOGRAPHY; ARTERIOGRAPHY; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; EVENT FREE SURVIVAL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; LONG TERM CARE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CHRONIC DISEASE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; MYOCARDIAL ISCHEMIA; OBSERVER VARIATION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; STENTS; TREATMENT OUTCOME;

EID: 78651259416     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1127     Document Type: Article

References (86)

1. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP, et al; Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-1124.
2. Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: A metaanalysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg 2005; 130: 512-519.
3. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005; 46: 575-581.
4. Rodriguez AE, Baldi J, Pereira CF, Navia J, Rodriguez AM, Delacasa A, et al; ERACI II Investigators. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol 2005; 46: 582-588.
5. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, et al. Long-term outcomes for coronary artery bypass graft surgery vs. stent implantation. N Engl J Med 2005; 352: 2174-2183.
6. Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007; 115: 1082-1089.
7. Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: Six year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008; 118: 381-388.
8. Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodringuez A, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: A metaanalysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and II, and SoS trials. Circulation 2008; 118: 1146-1154.
9. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
10. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004; 109: 1942-1947.
11. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215-1223.
12. Katritsis DG, Karvouni E, Ioannidis JP. Meta-analysis comparing drug-eluting stents with bare-metal stents. Am J Cardiol 2005; 95: 640-643.
13. Indolfi C, Pavia M, Angelillo IF. Drug eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol 2005; 95: 1146-1152.
14. Kastrati A, Dibra A, Eberle S, Mehilli J, Suárez de Lezo J, Goy JJ, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: Meta-analysis of randomized trials. JAMA 2005; 294: 819-825.
15. Schömig A, Dibra A, Windecker S, Mehilli J, de Lezo JS, Kaiser C, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1373-1380.
16. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
17. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
18. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008; 358: 331-341.
19. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronaryartery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972.
20. Li Y, Zheng Z, Xu B, Zhang S, Li W, Gao R, et al. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: Three-year follow-up results from a single institution. Circulation 2009; 119: 2040-2050.
21. Wang ZJ, Zhou YJ, Liu YY, Shi DM, Zhao YX, Guo YH, et al. Comparison of drug-eluting stents and coronary artery bypass grafting for the treatment of multivessel coronary artery disease in patients with chronic kidney disease. Circ J 2009; 73: 1228-1234.
22. Kim KS. PCI vs CABG in complicated diabetic patients. Circ J 2010; 74: 622-623.
23. Yamagata K, Kataoka Y, Kokubu N, Kasahara Y, Abe M, Nakajima H, et al. A 3-year clinical outcome after percutaneous coronary intervention using sirolimus-eluting stent and off-pump coronary artery bypass grafting for the treatment of diabetic patients with multivessel disease. Circ J 2010; 74: 671-678.
24. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary-artery bypass graft treatment in the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) trial. Circulation 2010; 121: 2645-2653.
25. Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Sergio Berti S, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: Comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010; 55: 1067-1075.
26. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110: 588-636 [Erratum, Circulation 2005; 111: 2013.]
27. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
28. Fragmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708-715.
29. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-1887.
30. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomised trial: Randomized intervention trial of unstable angina. Lancet 2002; 360: 743-751.
31. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: A collaborative meta-analysis of randomized trials. JAMA 2005; 293: 2908-2917.
32. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992; 326: 10-16.
33. Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997; 350: 461-468.
34. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-76.
35. Hueb W, Soares PR, Gersh BJ, César LA, Luz PL, Puig LB, et al. The Medicine, Angioplasty, or Surgery Study (MASS-II): A randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: One-year results. J Am Coll Cardiol 2004; 43: 1743-1751.
36. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, et al. Seven-year outcome in the RITA-2 trial: Coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003; 42: 1161-1170.
37. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516.
38. Shaw LJ, Berman DS, Maron DJ, Mancini GBJ, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117: 1283-1291.
39. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van't Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009; 360: 213-224.
40. Emond M, Mock MB, Davis K, Fisher LD, Holmes DR, Chaitman BR Jr, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation 1994; 90: 2645-2657.
41. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: A report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography: Coronary Revascularization Writing Group. Circulation 2009; 119: 1330-1352.
42. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51.
43. Volpi A, De Vita C, Franzosi MG, Geraci E, Maggioni AP, Mauri F, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: Results of the GISSI-2 data base. Circulation 1993; 88: 416-429.
44. Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, et al. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease: A randomized, comparative, multicenter study. J Am Coll Cardiol Interv 2008; 1: 469-479.
45. Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery: Survival data. Circulation 1983; 68: 939-950.
46. Myers WO, Davis K, Foster ED, Maynard C, Kaiser GC. Surgical survival in the Coronary Artery Surgery Study (CASS) Registry. Ann Thorac Surg 1985; 40: 245-260.
47. Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD, Schaff H, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease: Longterm CASS experience. Circulation 1955; 91: 2335-2344.
48. Barner HB, Standeven JW, Reese J. Twelve-year experience with internal mammary artery for coronary artery bypass. J Thorac Cardiovasc Surg 1985; 90: 668-675.
49. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5-12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985; 89: 248-258.
50. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314: 1-6.
51. Barner HB, Barnett MG. Fifteen- to twenty-one-year angiographic assessment of internal thoracic artery as a bypass conduit. Ann Thorac Surg 1994; 57: 1526-1528.
52. Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal-artery-grafts: Effects on survival over 15 year period. N Engl J Med 1996; 334: 216-219.
53. Beller GA, Zaret BL. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 2000; 101: 1465-1478.
54. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol 2004; 11: 171-185.
55. Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: Outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997; 95: 2037-2043.
56. Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: The SWISSI II randomized controlled trial. JAMA 2007; 297: 1985-1991.
57. Topol EJ, Nissen SE. Our preoccupation with luminology: The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995; 92: 2333-2342.
58. Tobis JM. Intravascular ultrasound: A fantastic voyage. Circulation 1990; 81: 2190-2192.
59. Yamagishi M, Hosokawa H, Saito S, Kanemitsu S, Chino M, Koyanagi S, et al. Coronary disease morphology and distribution determined by quantitative angiography and intravascular ultrasound. Circ J 2002; 66: 735-740.
60. Tobis J, Azarbal B, Slavin L. Assessment of intermediate severity coronary lesions in the catheterization laboratory. J Am Coll Cardiol 2007; 49: 839-848.
61. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Chuang YC, et al. Limitation of angiography in the assessment of plaque distribution in coronary artery disease: A systemic study of target lesion eccentricity in 1446 lesions. Circulation 1996; 93: 924-931.
62. Sun Z, Lin C, Davidson R, Dong C, Liao Y. Diagnostic value of 64-slice CT angiography in coronary artery disease: A systematic review. Eur J Radiol 2008; 67: 78-84.
63. Sun Z, Jiang W. Diagnostic value of multislice computed tomography angiography in coronary artery disease: A meta-analysis. Eur J Radiol 2006; 60: 279-286.
64. Gopalakrinshnan P, Wilson GT, Tak T. Accuracy of multislice computed tomography coronary angiography: A pooled estimate. Cardiol Rev 2008; 16: 189-196.
65. Ehara M, Surmely JF, Kawai M, Katoh O, Matsubara T, Terashima M, et al. Diagnostic accuracy of 64-slice computed tomography for detecting angiographically significant coronary artery stenosis in an unselected consecutive patient population. Circ J 2006; 70: 564-571.
66. Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: A randomized trial. Circulation 2001; 103: 2928-2934.
67. White CW, Wright CB, Doty DB. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? N Engl J Med 1984; 310: 819-824.
68. Meijboom WB, Van Mieghem CAG, van Pelt N, Weustink A, Pugliese F, Mollet NR, et al. Comprehensive assessment of coronary artery stenoses: Computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. J Am Coll Cardiol 2008; 52: 636-643.
69. Underwood SR, Anagnostopoulos C, Cerqueira M, Ell PJ, Flint EJ, Harbinson M, et al. Myocardial perfusion scintigraphy: The evidence. Eur J Nucl Med Mol Imaging 2004; 31: 261-291.
70. Moir S, Haluska BA, Jenkins C, Fathi R, Marwick TH. Incremental benefit of myocardial contrast to combined dipyridamole-exercise stress echocardiography for the assessment of coronary artery disease. Circulation 2004; 110: 1108-1113.
71. Beattie WS, Abdelnaem E, Wijeysundera DN, Buckley DN. A metaanalytic comparison of preoperative stress echocardiography and nuclear scintigraphy imaging. Anesth Analg 2006; 102: 8-16.
72. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: A meta-analysis. J Am Coll Cardiol 2007; 50: 1343-1353.
73. Pijls NH, van Son JAM, Kirkeeide RL, De Bruyne B, Gould KL. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 1993; 87: 1354-1367.
74. Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J, et al. Measurement of fractional flow reserve to assess the functional severity of coronary artery stenoses. N Engl J Med 1996; 334: 1703-1708.
75. De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol A, et al. Coronary flow reserve calculated from pressure measurements in humans: Validation with positron emission tomography. Circulation 1994; 89: 1013-1022.
76. De Bruyne B, Pijls NH, Bartunek J, Kulecki K, Bech JW, De Winter H, et al. Fractional flow reserve in patients with prior myocardial infarction. Circulation 2001; 104: 157-162.
77. Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, et al. Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation 2009; 120: 2207-2213.
78. Pijls NH, Van Gelder B, Van der Voort P, Peels K, Bracke FA, Bonnier HJ, et al. Fractional flow reserve: A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation 1995; 92: 3183-3193.
79. Hanekamp CE, Koolen JJ, Pijls NH, Michels HR, Bonnier HJ. Comparison of quantitative coronary angiography, intravascular ultrasound, and coronary pressure measurement to assess optimum stent deployment. Circulation 1999; 99: 1015-1021.
80. Berger A, Botman KJ, MacCarthy PA, Wijns W, Bartunek J, Heyndrickx GR, et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. J Am Coll Cardiol 2005; 46: 438-442.
81. Wongpraparut N, Yalamanchili V, Pasnoori V, Satran A, Chandra M, Masden R, et al. Thirty-month outcome after fractional flow reserve-guided versus conventional multivessel percutaneous coronary intervention. Am J Cardiol 2005; 96: 877-884.
82. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007; 49: 2105-2111.
83. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 2009; 119: 680-686.
84. Park SJ, Kim YH. Current status of percutaneous coronary intervention with drug-eluting stents in Asia. Circulation 2008; 118: 2730-2737.
85. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Shizuta S, Ehara N, et al. Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. Circulation 2008; 118(Suppl 1): S199-S209.
86. Nakamura M. Angiography is the gold standard and objective evidence of myocardial ischemia is mandatory if lesion severity is questionable: Indication of PCI for angiographically significant coronary artery stenosis without objective evidence of myocardial ischemia (Pro). Circ J 2011; 75: 204-210.